| AD | Alzheimer’s disease |
| FDA | Food and Drug Administration |
| AchE | acetylcholinesterase |
| NMDAR | N-methyl-d-aspartate receptor |
| MAPK | mitogen-activated protein kinase |
| ROS | reactive oxygen species |
| JNK | c-jun N-terminal kinase |
| ERK | extracellular signal-regulated kinase |
| TNF-α | tumor necrosis factor-α |
| IL-1 | interleukin-1 |
| LPS | lipopolysaccharide |
| ATP | adenosine triphosphate |
| CNS | central nervous systems |
| Aβ | amyloid-β |
| NFTs | neurofibrillary tangles |
| APP | amyloid precursor protein |
| PS | presenilin |
| NO | nitric oxide |
| NSAIDs | nonsteroidal anti-inflammatory drugs |
| iNOS | inducible nitric oxide synthase |
| NF-kB | nuclear factor kappa-light-chain-enhancer of activated B cells |
| LTP | long-term potentiation |
| LTD | long-term depression |
| mGluR | metabotropic glutamate receptor |
| AMPAR | α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor |
| BBB | blood-brain barrier |